Cargando…

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

INTRODUCTION: To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates. METHODS: Whole-exome sequencing was performed on 189 surgically resected LUSC. TMB was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Tao, Shi, Jinpeng, Dong, Zhengwei, Hou, Likun, Zhao, Chao, Li, Xuefei, Mao, Beibei, Zhu, Wei, Guo, Xianchao, Zhang, Henghui, He, Ji, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Wu, Chunyan, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625041/ https://www.ncbi.nlm.nih.gov/pubmed/31299995 http://dx.doi.org/10.1186/s13045-019-0762-1

Ejemplares similares

Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer
por: Jiang, Tao, et al.
Publicado: (2020)

Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma
por: Jiang, Tao, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
por: Jiang, Tao, et al.
Publicado: (2020)

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
por: Jiang, Tao, et al.
Publicado: (2017)

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
por: Dong, Zhengwei, et al.
Publicado: (2020)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma
por: Sui, Zhilin, et al.
Publicado: (2022)

Immune Infiltration Landscape in Lung Squamous Cell Carcinoma Implications
por: Zhao, Jungang, et al.
Publicado: (2020)

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
por: Wu, Fengying, et al.
Publicado: (2021)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
por: Chen, Lu, et al.
Publicado: (2019)

The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma
por: Guo, Liang, et al.
Publicado: (2021)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration
por: Chen, Chunji, et al.
Publicado: (2022)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
por: Yu, Xiaofei, et al.
Publicado: (2021)

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
por: Zhou, Juan, et al.
Publicado: (2019)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
por: HU, QIONG, et al.
Publicado: (2012)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Zhirui, et al.
Publicado: (2021)

Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy
por: Zhang, Xinhai, et al.
Publicado: (2020)

Single‐cell transcriptomics reveal the intratumoral landscape of infiltrated T‐cell subpopulations in oral squamous cell carcinoma
por: Chen, Jingtao, et al.
Publicado: (2021)

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
por: Jiang, Tao, et al.
Publicado: (2018)

Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder
por: Eismann, Lennert, et al.
Publicado: (2022)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

A novel immune-related prognostic model with surgical status to predict tumor immune cell infiltration and drug sensitivity in head and neck squamous cell carcinoma
por: Wang, Lang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eda5a14iq2p01sbm0jtip7j98e